Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, Uldrick TS, Ison G, Khozin S, Rubinstein WS, Schenkel C, Miller RS, Komatsoulis GA, Schilsky RL, Kim ES. Harvey RD, et al. Clin Cancer Res. 2021 May 1;27(9):2430-2434. doi: 10.1158/1078-0432.CCR-20-3857. Epub 2021 Feb 9. Clin Cancer Res. 2021. PMID: 33563634
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR. Ramalingam SS, et al. Among authors: harvey rd. J Thorac Oncol. 2013 Mar;8(3):369-72. doi: 10.1097/JTO.0b013e318282709c. J Thorac Oncol. 2013. PMID: 23407561 Free PMC article. Clinical Trial.
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR. Owonikoko TK, et al. Among authors: harvey rd. Clin Cancer Res. 2015 Apr 15;21(8):1859-68. doi: 10.1158/1078-0432.CCR-14-1998. Epub 2015 Feb 11. Clin Cancer Res. 2015. PMID: 25673697 Free PMC article. Clinical Trial.
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD. Sarantopoulos J, et al. Among authors: harvey rd. Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30. Clin Cancer Res. 2016. PMID: 26423795 Clinical Trial.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.
Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, Roach N, Schenkel C, Bruinooge SS, Cortazar P, Walker D, Fehrenbacher L. Lichtman SM, et al. Among authors: harvey rd. J Clin Oncol. 2017 Nov 20;35(33):3753-3759. doi: 10.1200/JCO.2017.74.4102. Epub 2017 Oct 2. J Clin Oncol. 2017. PMID: 28968172
American Society of Clinical Oncology Statement: Biosimilars in Oncology.
Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. Lyman GH, et al. Among authors: harvey rd. J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14. J Clin Oncol. 2018. PMID: 29443651 Review.
Reply to S.D. Lucio.
Lyman GH, Zon R, Harvey RD, Schilsky RL. Lyman GH, et al. Among authors: harvey rd. J Clin Oncol. 2018 Jul 10;36(20):2127. doi: 10.1200/JCO.2018.79.1780. Epub 2018 May 30. J Clin Oncol. 2018. PMID: 29847292 No abstract available.
Accelerating anticancer drug development - opportunities and trade-offs.
Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL. Nass SJ, et al. Among authors: harvey rd. Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Nat Rev Clin Oncol. 2018. PMID: 30275514 Review.
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD. Bilen MA, et al. Among authors: harvey rd. Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17. Cancer. 2019. PMID: 30329148 Free article.
263 results